Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.

Paul A. Gurbel, Kevin P. Bliden, Kathleen Butler, Mark J. Antonino, Cheryl Wei, Renli Teng, Lars Rasmussen, Robert F. Storey, Tonny Nielsen, John W. Eikelboom, Georges Sabe-Affaki, Steen Husted, Dean J. Kereiakes, David Henderson, Dharmendra V. Patel, Udaya S. Tantry

Research output: Contribution to journalArticlepeer-review

376 Scopus citations


BACKGROUND: The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown. METHODS AND RESULTS: Patients with stable coronary artery disease on aspirin therapy received a 300-mg clopidogrel load; nonresponders were identified by light transmittance aggregometry. In a 2-way crossover design, nonresponders (n=41) and responders (n=57) randomly received clopidogrel (600 mg/75 mg once daily) or ticagrelor (180 mg/90 mg twice daily) for 14 days during period 1. In period 2, all nonresponders switched treatment; half of the responders continued the same treatment, whereas the others switched treatment. Inhibition of platelet aggregation was higher in nonresponders treated with ticagrelor compared with clopidogrel (P<0.05). Treatment with ticagrelor among nonresponders resulted in a >10%, >30%, and >50% decrease in platelet aggregation from baseline in 100%, 75%, and 13% of patients, respectively. Platelet aggregation fell from 59+/-9% to 35+/-11% in patients switched from clopidogrel to ticagrelor and increased from 36+/-14% to 56+/-9% in patients switched from ticagrelor to clopidogrel (P<0.0001 for both). Platelet reactivity was below the cut points previously associated with ischemic risk measured by light transmittance aggregometry, VerifyNow P2Y(12) assay, and vasodilator-stimulated phosphoprotein phosphorylation in 98% to 100% of patients after ticagrelor therapy versus 44% to 76% of patients after clopidogrel therapy. CONCLUSIONS: Ticagrelor therapy overcomes nonresponsiveness to clopidogrel, and its antiplatelet effect is the same in responders and nonresponders. Nearly all clopidogrel nonresponders and responders treated with ticagrelor will have platelet reactivity below the cut points associated with ischemic risk. Clinical Trial Registration- Unique Identifier: NCT00642811.

Original languageEnglish (US)
Pages (from-to)1188-1199
Number of pages12
Issue number10
StatePublished - Mar 16 2010

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.'. Together they form a unique fingerprint.

Cite this